Zilberberg, Marya D.
Nathanson, Brian H.
Puzniak, Laura A.
Dillon, Ryan J.
Shorr, Andrew F.
Funding for this research was provided by:
The study was funded by a grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. (NA, NA, NA, NA, NA)
Article History
Received: 24 May 2022
Accepted: 21 September 2022
First Online: 5 October 2022
Declarations
:
: Because this study used already existing fully de-identified data, it was exempt from ethics review under US 45 CFR 46.101(b)4 [CitationRef removed]. All methods were carried out in accordance with relevant guidelines and regulations.
: Not applicable.
: MDZ’s employer, EviMed Research Group, LLC, has received research grant support from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. BHN’s employer, OptiStatim, LLC, has received support from EviMed Research Group, LLC. LAP is an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and stockholder in Merck & Co., Inc., Rahway, NJ, USA. RJD is an employee Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and stockholder in Merck & Co., Inc., Rahway, NJ, USA. AFS is a consultant to and has received research grant support from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. MDZ and AFS have received grant support and/or have served as consultants to Spero, Melinta, Tetraphase, Pfizer, Astellas, Shionogi, The Medicines Company, Lungpacer, and Theravance.